Carlyle Group Inc. - 28 Aug 2025 SCHEDULE 13G/A Report for Phathom Pharmaceuticals, Inc. Common Stock, par value $0.0001 per share (PHAT)

Filing Manager
Carlyle Group Inc.
Reporting Manager
Carlyle Group Inc.
Security
Phathom Pharmaceuticals, Inc. Common Stock, par value $0.0001 per share
Symbol
PHAT
Shares outstanding
71,363,429 shares
Disclosed Ownership
3,496,808 shares
Ownership
4.9%
Form type
SCHEDULE 13G/A
Filing time
28 Aug 2025, 16:30:04 UTC
Date of event
28 Aug 2025
SEC
View on sec.gov

Quoteable Key Fact

"Carlyle Group Inc. disclosed 4.9% ownership in Phathom Pharmaceuticals, Inc. Common Stock, par value $0.0001 per share (PHAT) on 28 Aug 2025."

Quick Takeaways

  • Carlyle Group Inc. filed SCHEDULE 13G/A for Phathom Pharmaceuticals, Inc. Common Stock, par value $0.0001 per share (PHAT).
  • Disclosed ownership: 4.9%.
  • Date of event: 28 Aug 2025.

What Changed

  • No earlier schedule filing is available for direct comparison.
  • Current filing was accepted on 28 Aug 2025, 16:30.

Why This Matters

  • This page explains what this Schedule 13D/13G filing tells you before manager-level rows.
  • You can verify ownership claims directly against the original SEC filing.

Source Evidence

Backed by Schedule 13D/13G

Beneficial ownership values are sourced from the original SEC Schedule 13D/13G filing.

See Original Filing

Reporting Managers (11)

Name Ownership Shares Owned sole voting power shared voting power Signature Title CIK
Carlyle Group Inc. 4.9% 3,496,808 0 3,496,808 /s/ Anne Frederick, Attorney-in-fact John C. Redett, Chief Financial Officer
Carlyle Holdings I GP Inc. 4.9% 3,496,808 0 3,496,808 /s/ Anne Frederick, Attorney-in-fact John C. Redett, Managing Director and Chief Financial Officer
Carlyle Holdings I GP Sub L.L.C. 4.9% 3,496,808 0 3,496,808 By: Carlyle Holdings I GP Inc., its sole member, By: /s/ Anne Frederick, Attorney-in-fact John C. Redett, Managing Director and Chief Financial Officer
Carlyle Holdings I L.P. 4.9% 3,496,808 0 3,496,808 /s/ Anne Frederick, Attorney-in-fact John C. Redett, Managing Director
CG Subsidiary Holdings L.L.C. 4.9% 3,496,808 0 3,496,808 /s/ Anne Frederick, Attorney-in-fact John C. Redett, Managing Director
TC Group, L.L.C. 4.9% 3,496,808 0 3,496,808 /s/ Anne Frederick, Attorney-in-fact John C. Redett, Managing Director
Carlyle Investment Management L.L.C. 4.9% 3,496,808 0 3,496,808 By: /s/ Anne Frederick, Attorney-in-fact John C. Redett, Chief Financial Officer
Carlyle Genesis UK LLC 4.9% 3,496,808 0 3,496,808 By: Carlyle Investment Management L.L.C., its sole member, By: /s/ Anne Frederick, Attorney-in-fact John C. Redett, Chief Financial Officer
Abingworth LLP 4.9% 3,496,808 0 3,496,808 By: /s/ Emma O'Reilly Emma O'Reilly, Authorized Signatory
Abingworth Bioventures 8 LP 2.9% 2,061,702 0 2,061,702 By: /s/ Emma O'Reilly Emma O'Reilly, Authorized Signatory
Abingworth Bioventures VII LP 2% 1,435,106 0 1,435,106 By: /s/ Emma O'Reilly Emma O'Reilly, Authorized Signatory